Literature DB >> 7989123

Effects of type-I and -II interferons on 90K antigen expression in ovarian carcinoma cells.

C Marth1, A Dreps, C Natoli, A G Zeimet, T Lang, M Widschwendter, G Daxenbichler, A Ullrich, S Iacobelli.   

Abstract

Antigen 90K is produced by several tumor-cell lines and by patients with cancer. Its function has not yet been clarified, although recent reports suggest that it plays a role in the tumor-host relationship--for example by stimulation of natural killer and lymphokine-activated killer-cell activity. Previous studies have indicated that 90K expression may be under the influence of interferon-alpha. Here, we provide evidence that both interferon-alpha and -gamma can enhance the secretion of 90K and augment the level of specific mRNA expression in 3 ovarian carcinoma cell lines (OVCAR-3, HTB-77 and SKOV-6). However, interferon-gamma leads to depletion of cellular 90K whereas interferon-alpha increases both secreted and cellular 90K levels. In equimolar concentrations, Interferon-alpha was always superior to interferon-gamma in augmenting 90K protein or mRNA levels. Combinations of TNF with interferon-gamma were highly synergistic both in reducing cell proliferation and in increasing 90K secretion and mRNA expression. This synergism was seen to a lesser extent with interferon-alpha.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7989123     DOI: 10.1002/ijc.2910590617

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  9 in total

1.  Elevated levels of circulating immunostimulatory 90K in Henoch-Schoenlein purpura.

Authors:  P Pelliccia; C Natoli; M T Petitti; A Verrotti; F Chiarelli; S Iacobelli
Journal:  J Clin Immunol       Date:  1999-03       Impact factor: 8.317

2.  Elevated plasma levels of 90K (Mac-2 BP) immunostimulatory glycoprotein in HIV-1-infected children.

Authors:  B Gröschel; J J Braner; M Funk; R Linde; H W Doerr; J Cinatl; S Iacobelli
Journal:  J Clin Immunol       Date:  2000-03       Impact factor: 8.317

3.  Differential effect on TCR:CD3 stimulation of a 90-kD glycoprotein (gp90/Mac-2BP), a member of the scavenger receptor cysteine-rich domain protein family.

Authors:  B Silvestri; F Calderazzo; V Coppola; A Rosato; S Iacobelli; C Natoli; A Ullrich; I Sures; M Azam; C Brakebush; L Chieco-Bianchi; A Amadori
Journal:  Clin Exp Immunol       Date:  1998-09       Impact factor: 4.330

Review 4.  Gal-3BP in Viral Infections: An Emerging Role in Severe Acute Respiratory Syndrome Coronavirus 2.

Authors:  Valentina Gallo; Alyexandra Arienzo; Stefano Iacobelli; Valentina Iacobelli; Giovanni Antonini
Journal:  Int J Mol Sci       Date:  2022-06-30       Impact factor: 6.208

5.  High serum levels of soluble CD44 variant isoform v5 are associated with favourable clinical outcome in ovarian cancer.

Authors:  A G Zeimet; M Widschwendter; M Uhl-Steidl; E Müller-Holzner; G Daxenbichler; C Marth; O Dapunt
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

6.  90K, an interferon-stimulated gene product, reduces the infectivity of HIV-1.

Authors:  Veronika Lodermeyer; Kristina Suhr; Nicola Schrott; Christian Kolbe; Christina M Stürzel; Daniela Krnavek; Jan Münch; Christian Dietz; Tanja Waldmann; Frank Kirchhoff; Christine Goffinet
Journal:  Retrovirology       Date:  2013-10-24       Impact factor: 4.602

Review 7.  A review of studies of the proteomes of circulating microparticles: key roles for galectin-3-binding protein-expressing microparticles in vascular diseases and systemic lupus erythematosus.

Authors:  Christoffer T Nielsen; Ole Østergaard; Niclas S Rasmussen; Søren Jacobsen; Niels H H Heegaard
Journal:  Clin Proteomics       Date:  2017-04-08       Impact factor: 3.988

Review 8.  Role of galectin 3 binding protein in cancer progression: a potential novel therapeutic target.

Authors:  Emily Capone; Stefano Iacobelli; Gianluca Sala
Journal:  J Transl Med       Date:  2021-09-26       Impact factor: 5.531

9.  M2BP inhibits HIV-1 virion production in a vimentin filaments-dependent manner.

Authors:  Qin Wang; Xiaolin Zhang; Yuling Han; Xinlu Wang; Guangxia Gao
Journal:  Sci Rep       Date:  2016-09-08       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.